Zacks: Analysts Expect Edwards Lifesciences Co. (NYSE:EW) to Announce $0.53 EPS

Equities research analysts forecast that Edwards Lifesciences Co. (NYSE:EW) will announce $0.53 earnings per share for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Edwards Lifesciences’ earnings. The lowest EPS estimate is $0.51 and the highest is $0.56. Edwards Lifesciences reported earnings of $0.51 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.9%. The company is expected to report its next quarterly earnings report on Wednesday, October 20th.

According to Zacks, analysts expect that Edwards Lifesciences will report full year earnings of $2.26 per share for the current financial year, with EPS estimates ranging from $2.23 to $2.30. For the next year, analysts expect that the firm will report earnings of $2.57 per share, with EPS estimates ranging from $2.32 to $2.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 29th. The medical research company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.09. The company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.29 billion. Edwards Lifesciences had a return on equity of 29.73% and a net margin of 29.69%.

Several research firms recently weighed in on EW. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $93.00 to $105.00 and gave the company a “neutral” rating in a research report on Tuesday, August 3rd. Jefferies Financial Group lifted their target price on Edwards Lifesciences from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, July 30th. Canaccord Genuity lifted their target price on Edwards Lifesciences from $103.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, July 30th. Piper Sandler lifted their target price on Edwards Lifesciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday, July 27th. Finally, Stifel Nicolaus lifted their target price on Edwards Lifesciences from $103.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, July 30th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Buy” and an average target price of $116.33.

In related news, VP Huimin Wang sold 6,350 shares of the business’s stock in a transaction that occurred on Wednesday, September 8th. The stock was sold at an average price of $121.25, for a total value of $769,937.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of the company’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $122.25, for a total value of $1,350,862.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 96,530 shares of company stock worth $11,055,715. Insiders own 1.35% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Baldrige Asset Management LLC purchased a new stake in Edwards Lifesciences during the second quarter worth $31,000. Bedel Financial Consulting Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $31,000. Wagner Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $35,000. Concord Wealth Partners lifted its holdings in shares of Edwards Lifesciences by 106.5% during the 1st quarter. Concord Wealth Partners now owns 446 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 230 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $41,000. Institutional investors own 80.13% of the company’s stock.

NYSE EW opened at $118.50 on Wednesday. The company has a market capitalization of $73.86 billion, a PE ratio of 50.86, a price-to-earnings-growth ratio of 3.40 and a beta of 1.08. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.89 and a current ratio of 3.75. The business’s fifty day moving average is $115.06 and its 200 day moving average is $100.68. Edwards Lifesciences has a fifty-two week low of $70.92 and a fifty-two week high of $123.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Featured Article: How is a management fee different from a performance fee?

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.